Therapy News and Research

RSS

Targeted Genetics acquires Biocontrol

Targeted Genetics Corporation, today announced the completion of the acquisition of Biocontrol Limited.

7 Jan 2011

Study finds combined treatments safe and effective for severe acute pancreatitis

The use of combined treatments for severe acute pancreatitis is safe and effective in managing the disease, resulting in shorter hospitalizations and fewer radiological procedures than standard therapy, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. In a related study, doctors found that patients with infected pancreatic necrosis were able to avoid surgery through primary conservative treatment, which is in-patient medical treatment.

7 Jan 2011

ASBP raises concern over FDA recommendations to lower BMI requirements for lap-band surgery

The American Society of Bariatric Physicians (ASBP) is concerned that the FDA advisory panel recommended lowering the BMI requirement for lap-band surgery, while the FDA recently denied two new obesity medications. Bariatric surgery is drastic and expensive and carries higher morbidity and mortality risks than lifestyle interventions or medication. Patients who could have otherwise lost weight in a non-surgical medical bariatric program may now be encouraged to skip medical therapy and jump directly to surgery.

7 Jan 2011

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Pharmasset, Inc., announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study.

7 Jan 2011

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Plexxikon, Inc., announced today that it has signed an agreement with Genentech to co-promote PLX4032 (RG7204) in the United States. PLX4032, an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation, is being tested in late-stage clinical trials for the treatment of metastatic melanoma.

7 Jan 2011

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas), for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV).

7 Jan 2011

Biomarker study yields diagnostic blood test candidate for detection of Alzheimer's disease

OPKO Health, Inc. today announced the publication of a biomarker study yielding its diagnostic blood test candidate for the detection of Alzheimer's disease.

7 Jan 2011

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

7 Jan 2011

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys, Inc. today announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem to patients being treated for leukemia or other blood born cancers.

7 Jan 2011

Curis announces selection of CUDC-907 as development candidate for cancer

Curis, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase and histone deacetylase as a development candidate from its targeted cancer programs.

7 Jan 2011

Better monitoring, new techniques reduce anesthesia-related maternal deaths

The number of women who die from complications of anesthesia during childbirth has plummeted 59 percent over the last two decades thanks to improved monitoring and better medical techniques, according to a recent study.

7 Jan 2011

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate.

7 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

CeNeRx commences TriRima Phase II trial for treatment resistant depression

CeNeRx BioPharma, today reported that it has initiated a Phase II trial of its new formulation of TriRima, the company's novel antidepressant in development as monotherapy for treatment resistant depression.

7 Jan 2011

Robo4 molecule may improve bone marrow transplants: Study

Researchers at the University of California, Santa Cruz, have identified a key molecule for establishing blood stem cells in their niche within the bone marrow. The findings, reported in the January issue of Cell Stem Cell, may lead to improvements in the safety and efficiency of bone marrow transplants.

7 Jan 2011

Dade Medical College officially launches new School of Continuing Education on Jan 22

Dade Medical College will officially introduce its new School of Continuing Education on January 22. This new division will begin offering non-credit courses for students and working professionals.

6 Jan 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Skilled Healthcare Group updates 2010 full year non-GAAP earnings estimates

Skilled Healthcare Group, Inc. today announced it has updated its 2010 full year non-GAAP earnings estimates and expects consolidated revenue to be approximately $816 million to $819 million, Adjusted EBITDAR to be approximately $138.9 million to $140.7 million and Adjusted EBITDA to be approximately $119.7 million to $121.5 million. The Company expects adjusted earnings per diluted share for 2010 to be between $1.01 and $1.04.

6 Jan 2011

InHealth awards grant to assess effects of hip replacement therapy on aging populations

The Institute for Health Technology Studies has awarded a grant of $240,000 to an international consortium of researchers, for a study that will assess the effects of hip replacement therapy on the employment and retirement decisions of older adults. Led by researchers at the Universit- Bocconi (Milan), the consortium also includes investigators at the University of York (York, UK), and the Johns Hopkins University School of Public Health (Baltimore).

6 Jan 2011

Therapy News and Research

Targeted Genetics acquires Biocontrol

Study finds combined treatments safe and effective for severe acute pancreatitis

ASBP raises concern over FDA recommendations to lower BMI requirements for lap-band surgery

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Biomarker study yields diagnostic blood test candidate for detection of Alzheimer's disease

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Curis announces selection of CUDC-907 as development candidate for cancer

Better monitoring, new techniques reduce anesthesia-related maternal deaths

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

CeNeRx commences TriRima Phase II trial for treatment resistant depression

Robo4 molecule may improve bone marrow transplants: Study

Dade Medical College officially launches new School of Continuing Education on Jan 22

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Skilled Healthcare Group updates 2010 full year non-GAAP earnings estimates

InHealth awards grant to assess effects of hip replacement therapy on aging populations

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News